Early encouraging UC Davis trial data on cell therapy for spina bifida
Professor Paul Knoepfler, Ph.D.
A Lancet paper is sparking excitement about an investigational cell therapy for spina bifida.
Here’s the study: Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study. Myelomeningocele is the most severe manifestation of spina bifida
The work was led by my UC Davis colleagues Diana Farmer and Aijun Wang. The trial is called Cellular Therapy for In Utero Repair of Myelomeningocele. I was not involved in the...